New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
14:25 EDTCTRP, SWKS, RPRX, PII, LXKOptions with decreasing volatility: CTRP SWKS RPRX PII LXK
News For CTRP;SWKS;RPRX;PII;LXK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 25, 2014
18:50 EDTPIIPolaris Industries backs FY14 EPS view $6.48-$6.58, consensus $6.59
Subscribe for More Information
15:05 EDTCTRPData suggest Ctrip.com may beat Q3 revenue guidance, says Piper Jaffray
Piper Jaffray said its analysis of China hotel and air travel data in the first two months of Q3 suggests Ctrip.com should at least hit the high end of its 30%-35% revenue growth forecast and may beat it, but by a lower amount than the company has previously beat in prior quarters. The firm maintains its Neutral rating on Ctrip, citing the volatility in China travel fundamentals.
10:33 EDTRPRXOptions with decreasing implied volatility
Options with decreasing implied volatility: VHC RPRX SFLY VNET YHOO RHT KMX BBBY CCL ACN
September 24, 2014
11:04 EDTRPRXOptions with decreasing implied volatility
Subscribe for More Information
10:18 EDTPIIPolaris Industries partners with Costco
Polaris Industries (PII) announced that it will partner with the Costco's (COST) Auto Program as the exclusive promotional partner for its powersports division. Costco members will be able to access special pricing and promotional incentives on select Polaris products at participating dealers in the U.S. As a partner in the Costco Auto Program, Polaris, Victory and GEM branded products will be on display inside select Costco warehouses.
09:59 EDTSWKSOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Ameren (AEE) initiated with a Buy at Ladenburg... Autoliv (ALV) initiated with an Outperform at Exane BNP Paribas... BNY Mellon (BK) initiated with a Neutral at Citigroup... Burlington Stores (BURL) initiated with a Neutral at Credit Suisse... Cameron (CAM) initiated with a Market Perform at Wells Fargo... CoreLogic (CLGX) initiated with an Overweight at Piper Jaffray... FMC Technologies (FTI) initiated with a Market Perform at Wells Fargo... FNFV (FNFV) initiated with a Neutral at Piper Jaffray... Fidelity National (FNF) initiated with an Overweight at Piper Jaffray... First American (FAF) initiated with a Neutral at Piper Jaffray... Freeport McMoRan (FCX) initiated with an Outperform at Scotia Capital... Helmerich & Payne (HP) initiated with an Outperform at Wells Fargo... HomeAway (AWAY) initiated with a Buy at SunTrust... IMS Health (IMS) initiated with a Buy at Topeka... Nabors Industries (NBR) initiated with an Outperform at Wells Fargo... National Oilwell (NOV) initiated with a Market Perform at Wells Fargo... Northern Trust (NTRS) initiated with a Neutral at Citigroup... Pacific Drilling (PACD) initiated with a Market Perform at Wells Fargo... Paragon Offshore (PGN) initiated with a Market Perform at Wells Fargo... Patterson-UTI Energy (PTEN) initiated with an Outperform at Wells Fargo... Pioneer Energy (PES) initiated with an Outperform at Wells Fargo... Realogy (RLGY) initiated with an Overweight at Piper Jaffray... Ruckus Wireless (RKUS) initiated with a Neutral at SunTrust... Sarepta (SRPT) initiated with an Outperform at Credit Suisse... Skyworks (SWKS) initiated with a Buy at MKM Partners... State Street (STT) initiated with a Buy at Citigroup... Ubiquiti Networks (UBNT) initiated with a Buy at SunTrust... Wafergen Biosystems (WGBS) initiated with a Buy at Brean Capital.
07:00 EDTSWKSSkyworks initiated with a Buy at MKM Partners
Target $68.
September 23, 2014
10:17 EDTCTRPCTA president sees Chinese spending $155B overseas this year, China Daily says
Subscribe for More Information
September 22, 2014
13:57 EDTRPRXRepros Therapeutics volatility increases on wide price movement
Repros Therapeutics overall option implied volatility of 128 is above its 26-week average of 89 according to Track Data, suggesting large price movement.
09:18 EDTRPRXRepros Therapeutics provides update on Androxal
Subscribe for More Information
September 19, 2014
08:11 EDTSWKSTriQuint chip among those in iPhone 6 Plus, iFixit reports
Subscribe for More Information
08:03 EDTSWKSInvenSense, NXP, RF Micro chips included in iPhone 6, iFixit reports
Subscribe for More Information
08:03 EDTSWKSSkyworks average iPhone content rose, says Craig-Hallum
Craig-Hallum believes that Skyworks' average content in the iPhone6/6+ rose to a little over $5.50, up from an average of around $4.80 in the iPhone 5S/5C. The firm expects Skyworks' to report beat and raise results. It keeps a $62 price target and Buy rating on the shares.
September 18, 2014
13:38 EDTRPRXRepros needed unique Androxal label even before ADCOM panel, says Ladenburg
Ladenburg said that given the FDA advisory committee's 20 to 1 vote that it believes the FDA will likely revise testosterone replacement therapy labels to restrict their use in hypogonadal patients with clear etiology. However, Ladenburg added that Repros was always going to have to establish a unique label for Androxal and the firm believes that the company's ongoing and completed trials will provide sufficient data for filing and approval by the FDA in secondary hypogonadism. The firm maintains its Buy rating and $35 price target on Repros.
12:45 EDTRPRXOn The Fly: Midday Wrap
Subscribe for More Information
11:15 EDTRPRXRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
10:52 EDTRPRXOptions with increasing implied volatility
Options with increasing implied volatility: RPRX VALE NLY AGNC
07:19 EDTRPRXRepros Therapeutics sell-off overdone, says Brean Capital
Brean Capital said the selling in Repros Therapeutics is overdone after an FDA panel voted overwhelmingly in support for a more restrictive label that limits the use of TRT drugs to only patients with classic hypogonadism. The firm feels since Androxal has not been targeting age-related hypogonadism it does not deserve to be negatively impacted by yesterday's ruling. Brean Capital maintains its Buy rating on Repros Therapeutics and $41 price target on the shares.
07:00 EDTRPRXRepros Therapeutics price target lowered to $13 from $24 at Piper Jaffray
Subscribe for More Information
06:10 EDTRPRXFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use